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comparable with non-steroidal anti-inflammatory
agents in mouse writhing test
Yu-feng Su1,5, Yu-Chiao Yang2, Hseng-Kuang Hsu3, Shiuh-Lin Hwang1,4, Kung-Shing Lee1,4, Ann-Shung Lieu1,4,
Te-Fu Chan4,6 and Chih-Lung Lin1,4*Abstract
Background: The antinociceptive effect of an aqueous extract from the leaves of Toona sinensis (TS, [A. Juss.,
M. Roem.]) was studied using the writhing test in mice.
Methods: Different extraction fractions from TS leaf extracts (TSL1 to TSL5) were administered orally 1 h before
intraperitoneal injection of acetic acid.
Results: After treatment with TSL1, TSL2, TSL3, TSL4, and TSL5 at a dose of 1 g/kg, the respective writhing
responses were 39.9% (P < 0.001), 19.9% (P < 0.05), 11.7% (P = 0.052), 8.1% (P = 0.188), and 11.4% (P = 0.057) lower
than the control group. Mice treated with TSL1 at 1 g/kg (39.9%, P < 0.001), 0.3 g/kg (38.0%, P < 0.001), 0.1 g/kg
(46.9%, P < 0.001), and 0.03 g/kg (31.1%, P < 0.001) had significantly lower writhing responses compared with
control mice. A time-course experiment was performed, which involved oral administration of TSL1 (0.1 g/kg) at 0,
0.5, 1, 2, and 6 h before acetic acid intraperitoneal injection. The most effective dose of TSL1 was 0.1 g/kg orally,
with the effect beginning 30 min before treatment and persisting until 6 h.
Conclusions: This study showed that TS has anti-visceral pain properties comparable with those of rofecoxib
(a cyclooxygenase-2 inhibitor) and diclofenac, which suggests promise for the treatment of intractable visceral pain
in humans.
Keywords: Toona sinensis, Visceral pain, Mouse writhing test, Non-steroidal anti-inflammatory drug (NSAID)Background
Toona sinensis (TS, [A. Juss. M. Roem.]), also known as
Cedrela sinensis, Chinese mahogany cedar, or Chinese
Toona, is a tree in the Meliaceae family that is widely
distributed throughout Asia [1]. The leaves and young
shoots of TS can be eaten, and almost every part of TS,
including seeds, bark, root bark, petioles, and leaves,
have been used medicinally in eastern Asia. The leaves
of TS have been found to have anti-inflammatory, anal-
gesic, and antiparasitic effects, and can act as an antidote
and inhibit boil growth. In traditional medical systems,
TS extracts have been used to treat enteritis, dysentery,* Correspondence: chihlung1@yahoo.com
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unless otherwise stated.carbuncles, boils, dermatitis, scabies, tinea blanca, and
itch [2-5]. Aqueous extracts of leaves of TS have also
been used to lower blood pressure associated with
diabetes. A number of compounds including retinoids,
vitamins B and C, o-coumaric acid, kaempferol, methyl
gallate, quercetin, afzelin, quercitrin, isoquercitrin, and
rutin have been isolated from the leaves of TS [5]. Ex-
tracts from the leaves of TS exert potent antiproliferative
and apoptotic effects on human ovarian and lung cancer
cells [6-8]. Methyl gallate isolated from TS was found to
have a protective effect in hydrogen peroxide-induced
oxidative stress and DNA damage in Madin-Darby ca-
nine kidney (MDCK) cells [9]. Moreover, TS can induce
lipolysis in differentiated 3 T3-L1 adipocytes and en-
hance glucose uptake in 3 T3-L1 adipocytes [10,11]. TS
was also shown to inhibit viral attachment (influenza A,
H1N1) through significant downregulation of adhesionis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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IL-8, and fractalkine) and may be used as an alternative
treatment and prophylaxis against pandemic influenza A
(H1N1) virus [12].
Twenty-seven percent of cancer-related pain originates
from the abdominal region [13]. Despite more efficient
use of narcotics and intrathecal opioids, visceral pain in
patients with abdominal cancer is still difficult to control.
A variety of ablative surgeries have been proposed to treat
intractable cancer-related abdominal pain, and some neu-
roablative procedures interrupting the spinothalamic tract
and related pathways have been used. However, their use
is limited because of significant complications, including a
decrease in proprioception, dysesthesia, transient paresis,
sphincter dysfunction, and even death [14].
This study was designed to evaluate the antinocicep-
tive effect of different leaf extracts from TS on a visceral
pain writhing test in mice.
Methods
Plant material
The leaves used in this preparation were obtained from
TS grown in Tuku (Yunlin County, Taiwan) and were
picked and washed thoroughly with water. A voucher
specimen (FY-001) was characterized by Dr. Horng-Liang
Lay, Graduate Institute of Biotechnology, National Pingtung
University of Science and Technology, Pingtung County,
Taiwan, and deposited at Fooyin University, Kaohsiung.
Preparation and fractionation of TS leaf extracts
Reverse osmosis water was added to the leaves at a pro-
portion of 4 L to 1 kg of leaves. The mixture was heated
to a boil and maintained for 30 min. The mixture was
then cooled slowly for 2 h at room temperature. The
leaves were then removed, and the remaining liquid
was concentrated over low heat and filtered with a
sieve (70-mesh). The filtered concentrate was lyophi-
lized with a VirTis apparatus (SP Scientific, Gardiner
and Stone Ridge, New York, USA) to obtain a crude
extract (TSL1). After lyophilization, 100 g of leaves
yielded approximately 5–6 g of TSL1 powder. The
powder was then dissolved in 99.5% ethanol and centri-
fuged at 3000 rpm and 4°C (Beckman AvantiTM J-30I) for
12 min to yield a supernatant and pellet. The supernatant
was further lyophilized to obtain the powder TSL2. The
pellet was further lyophilized and then dissolved in 50%
ethanol. The 50% ethanol solution was centrifuged at 4°C
and 3000 rpm for 12 min to yield a supernatant and pre-
cipitate. The supernatant was lyophilized to obtain the
powder TSL3. The precipitate was lyophilized and then
dissolved in 25% ethanol. The 25% ethanol solution was
centrifuged at 4°C and 3000 rpm for 12 min to yield a
supernatant and precipitate. The supernatant was lyophi-
lized to obtain the powder TSL4. Finally, the precipitatewas dissolved in reverse osmosis water and centrifuged at
4°C and 3000 rpm for 12 min to yield a supernatant,
which was lyophilized to obtain the powder TSL5.
Animals
A total of 144 male imprinting control region (ICR) mice
(body weight = 24–30 g), aged 4–5 weeks, were used in
this study. Experimental protocols used in this study
were approved by the Kaohsiung Medical University ani-
mal research committee. One hundred and twelve ani-
mals were fasted overnight before dosing, and were
evenly divided into fourteen groups as follows. Group 1,
control group (treatment with vehicle, double distilled
water 10 ml/kg). Groups 2, 3, 4, 5, and 6 were treated
with 1 g/kg TSL1, TSL2, TSL3, TSL4, and TSL5, respect-
ively. Groups 7, 8, 9, and 10 were treated with TSL1 at
doses of 0.3, 0.1, 0.03, and 0.01 g/kg, respectively. Groups
11 and 12 were treated with 5- and 1.5-mg/kg doses, re-
spectively, of rofecoxib (a cyclooxygenase-2 [COX-2] in-
hibitor, Merck Pharmaceuticals Ltd., Whitehouse Station,
New Jersey, USA). Groups 13 and 14 were treated with 5-
and 10-mg/kg doses, respectively, of diclofenac (Novartis
Pharmaceuticals Ltd., Basel, Switzerland). All treatments
were administered orally (p.o.), 1 h before intraperitoneal
(i.p.) administration of acetic acid 1% (10 mg/kg). Another
32 animals were included in a time-course study. TSL1
(0.1 g/kg) was orally administered 0, 0.5, 2, and 6 h before
i.p. administration of 1% acetic acid (10 mg/kg).
Writhing test
Mice were p.o. administered with their respective treat-
ments. After 1 h, each animal was injected i.p. with 1%
acetic acid (10 mg/kg) and individually housed in a glass
cylinder on a flat glass floor. Time-course data were ob-
tained by orally administering TSL1 (0.1 g/kg) 0, 0.5, 1,
2, and 6 h before acetic acid administration. Immediately
after acetic acid injection, the number of writhes per
mouse was counted for 30 min. The writhing activity
consists of a contraction of the abdominal muscles to-
gether with a stretching of the hind limbs [14]. The per-
centage of inhibition was calculated using the following
ratio: (control mean − treated mean) × 100/control mean.
Statistical analysis
Results are expressed as mean ± standard deviation (S.D.)
and statistically analyzed by analysis of variance, followed
by Student’s t-test. A probability level lower than 0.05 was
considered as statistically significant.
Results
Antinociceptive effects induced by different doses of
TS fractions on the writhing test in mice are shown in
Table 1. After treatment with TSL1, TSL2, TSL3, TSL4,
and TSL5 at doses of 1 g/kg, the respective writhing
Table 1 Effect of oral administration of TS extract fractions,
rofecoxib, and diclofenac on abdominal writhing in mice
induced by intraperitoneal injection of acetic acid








TSL1 (1 g/kg) 76.9 ± 20.9 39.9% < 0.001
TSL2 (1 g/kg) 102.9 ± 28.3 19.5% < 0.05
TSL3 (1 g/kg) 112.8 ± 14.8 11.7% 0.052
TSL4 (1 g/kg) 117.4 ± 16.4 8.1% 0.188
TSL5 (1 g/kg) 113.3 ± 14.6 11.4% 0.057
TSL1 (0.3 g/kg) 79.3 ± 21.7 38.0% < 0.001
TSL1 (0.1 g/kg) 67.8 ± 20.7 46.9% < 0.001
TSL1 (0.03 g/kg) 85.0 ± 24.9 31.1% < 0.001
TSL1 (0.01 g/kg) 113.1 ± 17.2 11.7% 0.092
Rofecoxib (1.5 mg/kg) 93.4 ± 13.2 26.9% < 0.01
Rofecoxib (5 mg/kg) 84.6 ± 11.0 33.8% < 0.001
Diclofenac (5 mg/kg) 84.9 ± 13.1 33.5% < 0.001
Diclofenac (10 mg/kg) 72.0 ± 14.5 43.7% < 0.001
*Values are expressed as mean ± S.D. (n = 8).
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11.7% (P = 0.052), 8.1% (P = 0.188), and 11.4% (P = 0.057)
lower than that of the control group. Mice treated
with TSL1 at 1 g/kg (39.9%, P < 0.001), 0.3 g/kg
(38.0%, P < 0.001), 0.1 g/kg (46.9%, P < 0.001), and
0.03 g/kg (31.1%, P < 0.001) had significantly lower
writhing response compared with control mice, with
values ranging from 31.1–46.9% inhibition. However,
the writhing response in animals treated with 0.01 g/kg
TSL1 did not differ significantly when compared with the
control (11.7%, P = 0.092). The most effective dose of
TSL1 (0.1 g/kg p.o.) was used in the time course study,
with the effect beginning at 30 min of pre-treatment and
persisting until 6 h, as shown in Table 2.Table 2 Time-course effect of TSL1 (0.1 g/kg) on the










Control 127.8 ± 13.46 0.0
0.0 134.8 ± 11.7 −1.1% 0.285
0.5 102.1 ± 22.8 20.1% < 0.05
1.0 67.8 ± 20.7 46.9% < 0.001
2.0 85.3 ± 22.6 33.3% < 0.001
6.0 94.6 ± 14.0 25.9% < 0.001
*Values are expressed as mean ± S.D. (n = 8).Treatment with 1.5 and 5 mg/kg rofecoxib re-
duced writhing responses by 26.9% (P < 0.01) and 33.8%
(P < 0.001), respectively, compared with the control group.
Treatment with 5 and 10 mg/kg diclofenac, reduced
respective writhing responses by 33.5% (P < 0.001) and
43.7% (P < 0.001), compared with the control group
(Table 1). The antinociceptive effect of TSL1 (0.1 g/kg)
is comparable with that of rofecoxib and diclofenac
(P > 0.05).
Discussion
Cancer-related pain may originate from nociceptors in
bone (35%), soft tissue (45%), visceral structures (33%),
or may be neuropathic in origin (34%) [13]. Because of
the rapid progression of abdominal cancers, it is plaus-
ible that most visceral pain is because of visceral organ
inflammation. Treatment for visceral pain in advanced
cancer patients with either medication or surgery is crit-
ical to their quality of life. However, the results of com-
mon treatments are unsatisfactory. Clinical use of herbal
medicines could be an alternative strategy to treating
patients with intractable pain. The present study demon-
strated that the fractionated TS leaf extract given orally
in mice has analgesic properties in an acetic acid-
induced writhing model of nociception. We found that
the most significant antinociceptive effect was that of
TSL1 at a dose of 0.1 g/kg. Increased TSL1 dosage did
not increase the antinociceptive effects. However, TSL1
at a dosage of 0.01 g/kg had an antinociceptive effect
that was not significantly different from that of the con-
trol group. We hypothesize that TSL1 has various com-
ponents that interact negatively with increased dosage,
which reduces the antinociceptive effect. The results also
imply that possible receptor/ligand-gated mechanisms
may involve the antinociceptive effect of TSL1. Further
study should focus on the component that is responsible
for the anti-visceral pain activity of TSL1.
The writhing test is an experimental model used for
the screening of drugs with analgesic activity. The model
is induced by intraperitoneal injection of acetic acid,
which causes irritation. The writhing response is the
contraction of the abdominal muscles accompanying an
extension of the forelimbs and elongation of the body,
which is an established visceral inflammatory pain model
[15]. Both central and peripheral analgesic effects can be
tested with the writhing test. However, the lack of speci-
ficity in the writhing test should be taken into consider-
ation when interpreting these results until other tests
have been performed [16,17]. Nevertheless, a good rela-
tionship exists between the potencies of analgesics in
writhing assays and their clinical potencies. Our present
study confirmed the anti-visceral pain properties of
TS, which were comparable with those of diclofenac
and rofecoxib. Therefore, TS is a candidate for further
Su et al. BMC Complementary and Alternative Medicine  (2015) 15:70 Page 4 of 4investigation as an anti-visceral pain drug. However,
there is no evidence confirming the interactive effects
of TS pain mediators related to visceral pain, including
histamine, 5-hydroxytryptamine, kinins, acetylcholine,
substance P, and prostaglandins [18,19]. Further study
should be conducted to elucidate the exact mechanism
of action of TS leaf extract. Although presivous studies
with cell-lines showed TS extracts exert potent anti-
proliferative and apoptotic effects on human ovarian
and lung cancer cells [6-8], we did not observe signifi-
cant side effects or behavioral changes in the present
study. Furthermore objective and structured evaluation
of behavior and locomotor function also should be
included.
The antinociceptive effect of TSL1 was evident 30 min
after oral administration and lasted for 6 h. Therefore,
our results indicate that the analgesic compounds are
absorbed orally, and that pre-systemic metabolism does
not impede this effect.
Conclusions
The results of the present study provide evidence that
fractionated TS leaf extracts have antinociceptive effects
in a visceral pain mouse model. Further studies should
be conducted to elucidate the components responsible
for the pharmacological activity.
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